COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,725 Articles (22,913 medRxiv, 8,812 bioRxiv)

Most recent first Previous |  Page 1339: Articles 13381-13390  | Next

Is the BioNTech-Pfizer COVID-19 vaccination effective in elderly populations? Results from population data from Bavaria, Germany
Gomes, D., Beyerlein, A., Katz, K., Hoelscher, G., Nennstiel, U., Liebl, B., Ueberla, K., von Kries, R.
10.1101/2021.08.19.21262266 — Posted: 2021-08-21 Discussion: Onsite
Self-testing and vaccination against COVID-19 to minimize school closure
Colosi, E., Bassignana, G., Contreras, D. A., Poirier, C., Cauchemez, S., Yazdanpanah, Y., Lina, B., Fontanet, A., Barrat, A., Colizza, V.
10.1101/2021.08.15.21261243 — Posted: 2021-08-21 Discussion: Offsite
The burden of isolation to the individual: a comparison between isolation for COVID-19 and for other influenza-like illnesses in Japan
Tsuzuki, S., Ohmagari, N., Beutels, P.
10.1101/2021.08.19.21262267 — Posted: 2021-08-21
Regional comparisons of COVID reporting rates, burden, and mortality age-structure using auxiliary data sources
Van Gordon, M. M., Mwananyanda, L., Gill, C. J., McCarthy, K. A.
10.1101/2021.08.18.21262248 — Posted: 2021-08-21
Bias as a source of inconsistency in ivermectin trials for COVID-19: A systematic review
Izcovich, A., Peiris, S., Ragusa, M., Tortosa, F., Rada, G., Aldighieri, S., Reveiz, L.
10.1101/2021.08.19.21262304 — Posted: 2021-08-21
Virological characteristics of SARS-CoV-2 vaccine breakthrough infections in health care workers
Shamier, M. C., Tostmann, A., Bogers, S., De Wilde, J., IJpelaar, J., Van Der Kleij, W., De Jager, H., Haagmans, B., Molenkamp, R., Oude Munnink, B., van Rossum, C., Rahamat-Langendoen, J., Van Der Geest, N., Bleeker-Rovers, C., Wertheim, H., Koopmans, M., GeurtsvanKessel, C.
10.1101/2021.08.20.21262158 — Posted: 2021-08-21 Discussion: Onsite | Offsite
Rapid spread of a SARS-CoV-2 Delta variant with a frameshift deletion in ORF7a
Foster, C. S. P., Rawlinson, W. D.
10.1101/2021.08.18.21262089 — Posted: 2021-08-21
SARS-CoV-2 hijacks p38β/MAPK11 to promote viral protein translation
Higgins, C. A., Nilsson-Payant, B. E., Kurland, A., Adhikary, P., Golynker, I., Danziger, O., Panis, M., Rosenberg, B. R., tenOever, B. R., Johnson, J. R.
10.1101/2021.08.20.457146 — Posted: 2021-08-20
Platelet proteome analysis reveals an early hyperactive phenotype in SARS-CoV-2-infected humanized ACE2 mice
Subramaniam, S., Hekman, R. M., Jayaraman, A., O'Connell, A. K., Montanaro, P., Blum, B., Kenney, D., Ericsson, M., Ravid, K., A Crossland, N., Emili, A., Douam, F., Bosmann, M.
10.1101/2021.08.19.457020 — Posted: 2021-08-20
High-Spatiotemporal-Resolution Nanopore Sequencing of SARS-CoV-2 and Host Cell RNAs
Tombacz, D., Dormo, A., Gulyas, G., Csabai, Z., Prazsak, I., Kakuk, B., Harangozo, A., Jankovics, I., Denes, B., Boldogkoi, Z.
10.1101/2021.08.20.457128 — Posted: 2021-08-20

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).